These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16250644)

  • 81. Bivalent dopamine D2 receptor ligands: synthesis and binding properties.
    Kühhorn J; Hübner H; Gmeiner P
    J Med Chem; 2011 Jul; 54(13):4896-903. PubMed ID: 21599022
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 1.
    Takeuchi K; Kohn TJ; Honigschmidt NA; Rocco VP; Spinazze PG; Koch DJ; Nelson DL; Wainscott DB; Ahmad LJ; Shaw J; Threlkeld PG; Wong DT
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1903-5. PubMed ID: 12749894
    [TBL] [Abstract][Full Text] [Related]  

  • 84. N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.
    Newman AH; Cao J; Bennett CJ; Robarge MJ; Freeman RA; Luedtke RR
    Bioorg Med Chem Lett; 2003 Jul; 13(13):2179-83. PubMed ID: 12798330
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Design, synthesis and dopamine D4 receptor binding activities of new N-heteroaromatic 5/6-ring Mannich bases.
    Linz S; Müller J; Hübner H; Gmeiner P; Troschütz R
    Bioorg Med Chem; 2009 Jul; 17(13):4448-58. PubMed ID: 19481941
    [TBL] [Abstract][Full Text] [Related]  

  • 86. In vitro, molecular modeling and behavioral studies of 3-{[4-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl}-1,2-dihydroquinolin-2-one (D2AAK1) as a potential antipsychotic.
    Kaczor AA; Targowska-Duda KM; Budzyńska B; Biała G; Silva AG; Castro M
    Neurochem Int; 2016 Jun; 96():84-99. PubMed ID: 26964765
    [TBL] [Abstract][Full Text] [Related]  

  • 87. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
    Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H
    J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
    Dutta AK; Venkataraman SK; Fei XS; Kolhatkar R; Zhang S; Reith ME
    Bioorg Med Chem; 2004 Aug; 12(16):4361-73. PubMed ID: 15265488
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
    Zhang JY; Kowal DM; Nawoschik SP; Lou Z; Dunlop J
    Biochem Pharmacol; 2006 Feb; 71(4):521-9. PubMed ID: 16336943
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
    Terzioglu N; van Rijn RM; Bakker RA; De Esch IJ; Leurs R
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5251-6. PubMed ID: 15454206
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
    Rasmussen K; Benvenga MJ; Bymaster FP; Calligaro DO; Cohen IR; Falcone JF; Hemrick-Luecke SK; Martin FM; Moore NA; Nisenbaum LK; Schaus JM; Sundquist SJ; Tupper DE; Wiernicki TR; Nelson DL
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1265-77. PubMed ID: 16141369
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 93. 3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonists.
    Wustrow DJ; Smith WJ; Corbin AE; Davis MD; Georgic LM; Pugsley TA; Whetzel SZ; Heffner TG; Wise LD
    J Med Chem; 1997 Jan; 40(2):250-9. PubMed ID: 9003524
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy.
    Maier DL; Sobotka-Briner C; Ding M; Powell ME; Jiang Q; Hill G; Heys JR; Elmore CS; Pierson ME; Mrzljak L
    J Pharmacol Exp Ther; 2009 Jul; 330(1):342-51. PubMed ID: 19401496
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Synthesis and biological evaluation of 1-(4-(piperazin-1-yl)phenyl)pyridin-2(1H)-one derivatives as potential SSRIs.
    Xu T; Xue Y; Lu J; Jin C
    Eur J Med Chem; 2021 Nov; 223():113644. PubMed ID: 34182358
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Synthesis, computational studies and preliminary pharmacological evaluation of 2-[4-(aryl substituted) piperazin-1-yl] N, N-diphenylacetamides as potential antipsychotics.
    Kumar S; Wahi AK; Singh R
    Eur J Med Chem; 2011 Sep; 46(9):4753-9. PubMed ID: 21824691
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.
    Takahashi S; Sonehara K; Takagi K; Miwa T; Horikomi K; Mita N; Nagase H; Iizuka K; Sakai K
    Psychopharmacology (Berl); 1999 Aug; 145(3):295-302. PubMed ID: 10494578
    [TBL] [Abstract][Full Text] [Related]  

  • 98. 6-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors.
    Bromidge SM; Bertani B; Borriello M; Faedo S; Gordon LJ; Granci E; Hill M; Marshall HR; Stasi LP; Zucchelli V; Merlo G; Vesentini A; Watson JM; Zonzini L
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5653-6. PubMed ID: 18799312
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).
    Bromidge SM; Arban R; Bertani B; Bison S; Borriello M; Cavanni P; Dal Forno G; Di-Fabio R; Donati D; Fontana S; Gianotti M; Gordon LJ; Granci E; Leslie CP; Moccia L; Pasquarello A; Sartori I; Sava A; Watson JM; Worby A; Zonzini L; Zucchelli V
    J Med Chem; 2010 Aug; 53(15):5827-43. PubMed ID: 20590088
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for α(1)-adrenoceptors.
    Kristensen JL; Püschl A; Jensen M; Risgaard R; Christoffersen CT; Bang-Andersen B; Balle T
    J Med Chem; 2010 Oct; 53(19):7021-34. PubMed ID: 20857909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.